Otsuka
The new smartphone app, Rejoyn, will deliver treatment to patients taking antidepressant medication aimed at enhancing cognitive control of emotion.
During a discussion at ViVE 2023, panelists emphasized the need to interrogate data and know how it could be biased.
The three-year partnership seeks to derive insights that can be applied to Otsuka's products and other offerings.
Dr. Charlotte Jones-Burton, who leads Otsuka’s Global Clinical Development on Nephrology, discusses how COVID-19 has changed care.
Panelists at this morning's DTx West discuss how governments worldwide are looking at digital therapeutics.
The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients.
Also: Centauri Health Solutions acquires HCFS; UCSF researchers detail smartphone PPG-based diabetes detection.
The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.
The industry is better off viewing the the floundering deals between Onduo and Sanofi, Proteus and Otsuka, and Pear and Sandoz as a learning opportunity.
The digital pill maker's employees were brought back after the company secured $5 million in emergency funding, but CNBC's report suggests that several are now looking elsewhere for work.